Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-KIDNEY Kids
NCT07107945Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of empagliflozin in chronic kidney disease (CKD), sponsored by Boehringer Ingelheim. Started Dec 2025; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07107945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107945.